Citigroup set a $124.00 target price on Eli Lilly And Co (NYSE:LLY) in a report released on Tuesday, February 26th. The firm currently has a hold rating on the stock.
A number of other equities analysts have also recently weighed in on the stock. Barclays reaffirmed a buy rating and set a $130.00 price target on shares of Eli Lilly And Co in a research note on Sunday, January 20th. BMO Capital Markets lifted their target price on Eli Lilly And Co from $124.00 to $132.00 and gave the company an outperform rating in a research note on Monday, December 24th. They noted that the move was a valuation call. TheStreet raised Eli Lilly And Co from a c+ rating to a b+ rating in a research note on Tuesday, November 6th. UBS Group assumed coverage on Eli Lilly And Co in a research note on Wednesday, January 23rd. They set a buy rating and a $131.00 target price on the stock. Finally, Zacks Investment Research raised Eli Lilly And Co from a hold rating to a buy rating and set a $128.00 target price on the stock in a research note on Wednesday, November 28th. Ten research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $115.68.
Shares of NYSE LLY traded down $0.01 during midday trading on Tuesday, reaching $128.30. The company had a trading volume of 15,235,847 shares, compared to its average volume of 36,743,972. The stock has a market cap of $132.84 billion, a P/E ratio of 23.12, a P/E/G ratio of 2.58 and a beta of 0.33. Eli Lilly And Co has a 1 year low of $74.51 and a 1 year high of $130.75. The company has a current ratio of 1.73, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.03). The company had revenue of $6.44 billion during the quarter, compared to analysts’ expectations of $6.28 billion. Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The company’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.14 EPS. As a group, sell-side analysts forecast that Eli Lilly And Co will post 5.66 earnings per share for the current year.
In related news, insider Donald A. Zakrowski sold 1,000 shares of Eli Lilly And Co stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $128.50, for a total transaction of $128,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Alfonso G. Zulueta sold 4,000 shares of Eli Lilly And Co stock in a transaction that occurred on Thursday, January 31st. The stock was sold at an average price of $120.00, for a total value of $480,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 834,190 shares of company stock valued at $102,516,602. Corporate insiders own 0.11% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in LLY. Oregon Public Employees Retirement Fund grew its position in Eli Lilly And Co by 17,720.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 42,420,406 shares of the company’s stock worth $367,000 after acquiring an additional 42,182,367 shares during the last quarter. Norges Bank purchased a new stake in shares of Eli Lilly And Co in the fourth quarter worth $1,056,086,000. FMR LLC raised its position in shares of Eli Lilly And Co by 526.5% in the third quarter. FMR LLC now owns 7,444,216 shares of the company’s stock worth $798,838,000 after buying an additional 6,255,915 shares in the last quarter. Amundi Pioneer Asset Management Inc. raised its position in shares of Eli Lilly And Co by 165.4% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 6,012,822 shares of the company’s stock worth $695,804,000 after buying an additional 3,747,482 shares in the last quarter. Finally, BlackRock Inc. raised its position in shares of Eli Lilly And Co by 3.0% in the fourth quarter. BlackRock Inc. now owns 68,956,519 shares of the company’s stock worth $7,979,649,000 after buying an additional 2,030,845 shares in the last quarter. 78.69% of the stock is owned by institutional investors and hedge funds.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: Economic Reports
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.